- Kratom Craze: Science, Safety, and Regulation in the Age of Novel Products
-
Room 302‚ Convention Center
Chair: Ilona Jaspers, University of North Carolina at Chapel Hill
Co-Chair: Kym Gowdy, Ohio State University
Primary Endorser: Ethical, Legal, Forensics, and Societal Issues Specialty Section
Endorser(s): Inhalation and Respiratory Specialty SectionKratom (Mitragyna speciosa), a botanical native to Southeast Asia, has rapidly gained popularity in the United States with claims as being a remedy for pain, anxiety, and opioid withdrawal. The FDA has recently called for a ban of kratom and 7-hydroxymitragynine (also known as 7-OH), an alkaloid naturally found in small amounts in kratom, due to its potential opioid overdose effects. Its complex pharmacology, coupled with the emergence of novel formulations in a variety of consumer products, including edibles, drinks, and vaping products containing high levels of 7-OH, raises critical questions for toxicologists, clinicians, regulators, and potentially law enforcement. Despite widespread use, scientific understanding of kratom’s pharmacokinetics, safety profile, and abuse potential remains limited, and regulatory frameworks struggle to keep pace with evolving product trends. This Scientific Session will provide a multidisciplinary perspective on the 'Kratom Craze'. Topics to be covered will include multiple clinical case studies in which patients present with multiple health effects from kratom/7-OH use, a review of the pharmacokinetics of kratom alkaloids and findings from recent clinical trials, highlighting implications for therapeutic use and toxicity risk, discussions on emerging kratom-derived consumer products and why vaping products may present unique challenges regarding chemical stability, inhalation exposure, and associated toxicological concerns and how to address regulatory challenges, including classification ambiguities, enforcement gaps, and future policy directions regarding all kratom and 7-OH products. These evolving products challenge traditional FDA regulatory frameworks by blurring the boundaries between dietary supplements, drugs, and controlled substances. Despite widespread use, scientific understanding of kratom’s pharmacokinetics, safety profile, and abuse liability remains incomplete, complicating efforts by the FDA and other agencies to establish clear, evidence-based regulatory pathways. Attendees will gain insight into the science and policy issues surrounding kratom and its derivatives, equipping them to navigate this rapidly evolving product use landscape and contribute to evidence-based decision-making.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
